CoMFA and CoMSIA analysis of tetrahydroquinolines as potential antimalarial agents

SAR and QSAR in Environmental Research

Volumn 22, Issue 5-6, 2011, Pages 473-488

  Deshpande, S ^a   Jaiswal, S ^a   Katti, S B ^a   Prabhakar, Y S ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

3D QSAR; CoMFA; CoMSIA; Malaria; Pf PFT inhibitors; Tetrahydroquinolines

Indexed keywords

COMPUTATIONAL CHEMISTRY; CRYSTAL STRUCTURE; SULFUR COMPOUNDS;

3D-QSAR; ANTIMALARIAL AGENT; COCRYSTAL STRUCTURE; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE-MOLECULAR-SIMILARITY-INDICES ANALYSIS; MALARIA; PF-PFT INHIBITOR; PLASMODIUM FALCIPARUM; PROTEIN FARNESYLTRANSFERASE; TETRAHYDROQUINOLINES;

MOLECULES;

PLASMODIUM FALCIPARUM; RATTUS;

EID: 80051823372     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/1062936X.2011.569945     Document Type: Article

References (38)

1. P.J. Casey and M.C. Seabra, Protein prenyltransferases, J. Biol. Chem. 271 (1996), pp. 5289-5292.
2. A.D. Basso, P. Kirschmeier, and W.R. Bishop, Thematic Review Series: Lipid posttranslational modifications: Farnesyl transferase inhibitors, J. Lipid Res. 47 (2006), pp. 15-31.
3. Available at www.plasmodb.org
4. J. Ohkanda, J.W. Lockman, K. Yokoyama, M.H. Gelb, S.L. Croft, H. Kendrick, M.I. Harrell, J.E. Feagin, M.A. Blaskovich, S.M. Sebti, and A.D. Hamilton, Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity, Bioorg. Med. Chem. Lett. 11 (2001), pp. 761-764.
5. D. Chakrabarti, T. Da Silva, J. Barger, S. Paquette, H. Patel, S. Patterson, and C.M. Allen, Protein farnesyltransferase and protein prenylation in Plasmodium falciparum, J. Biol. Chem. 277 (2002), pp. 42066-42073.
6. J. Wiesner, K. Kettler, J. Sakowski, R. Ortmann, A.M. Katzin, E.A. Kimura, K. Silber, G. Klebe, H. Jomaa, and M. Schlitzer, Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo, Angew. Chem., Int. Ed. 43 (2004), pp. 251-254.
7. D. Carrico, J. Ohkanda, H. Kendrick, K. Yokoyama, M.A. Blaskovich, C.J. Bucher, F.S. Buckner, W.C. Van Voorhis, D. Chakrabarti, S.L. Croft, M.H. Gelb, S.M. Sebti, and A.D. Hamilton, In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability, Bioorg. Med. Chem. 12 (2004), pp. 6517-6526.
8. M.P. Glenn, S.Y. Chang, O. Hucke, C.L. Verlinde, K. Rivas, C. Horney, K. Yokoyama, F.S. Buckner, P.R. Pendyala, D. Chakrabarti, M.H. Gelb, W.C. Van Voorhis, S.M. Sebti, and A.D. Hamilton, Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites, Angew. Chem., Int. Ed. 44 (2005), pp. 4903-4906.
9. A. Ryckebusch, P. Gilleron, R. Millet, R. Houssin, A. Lemoine, N. Pommery, P. Grellier, C. Sergheraert, and J.P. Henichart, Novel N-(4-piperidinyl)benzamide antimalarials with mammalian protein farnesyltransferase inhibitory activity, Chem. Pharm. Bull. 53 (2005), pp. 1324-1326.
10. K. Kettler, J. Wiesner, K. Silber, P. Haebel, R. Ortmann, I. Sattler, H.M. Dahse, H. Jomaa, G. Klebe, and M. Schlitzer, Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3- benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity, Eur. J. Med. Chem. 40 (2005), pp. 93-101.
11. M.P. Glenn, S.Y. Chang, C. Horney, K. Rivas, K. Yokoyama, E.E. Pusateri, S. Fletcher, C.G. Cummings, F.S. Buckner, P.R. Pendyala, D. Chakrabarti, S.M. Sebti, M.H. Gelb, W.C. Van Voorhis,and A.D. Hamilton, Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites, J. Med. Chem. 49 (2006), pp. 5710-5727.
12. L. Nallan, K.D. Bauer, P. Bendale, K. Rivas, K. Yokoyama, C.P. Horney, P.R. Pendyala, D. Floyd, L.J. Lombardo, D.K. Williams, A. Hamilton, S. Sebti, W.T. Windsor, P.C. Weber, F.S. Buckner, D. Chakrabarti, M.H. Gelb, and W.C. Van Voorhis, Protein farnesyltransferase inhibitors exhibit potent antimalarial activity, J. Med. Chem. 48 (2005), pp. 3704-3713.
13. P. Bendale, S. Olepu, P.K. Suryadevara, V. Bulbule, K. Rivas, L. Nallan, B. Smart, K. Yokoyama, S. Ankala, P.R. Pendyala, D. Floyd, L.J. Lombardo, D.K. Williams, F.S. Buckner, D. Chakrabarti, C.L.M. Verlinde, W.C. VanVoorhis, and M.H. Gelb, Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials, J. Med. Chem. 50 (2007), pp. 4585-4605.
14. M.J. Polley, D.A. Winkler, and F.R. Burden, Broad-based quantitative structure-activity relationship modeling of potency and selectivity of farnesyltransferase inhibitors using a Bayesian regularized neural network, J. Med. Chem. 47 (2004), pp. 6230-6238.
15. M.P. Gonzalez, J. Caballero, A. Tundidor-Camba, A.M. Helguera, and M. Fernandez, Modeling of farnesyltransferase inhibition by some thiol and non-thiol peptidomimetic inhibitors using genetic neural networks and RDF approaches, Bioorg. Med. Chem. 14 (2006), pp. 200-213.
16. D.S. Puntambekar, R. Giridhar, and M.R. Yadav, 3d-Qsar studies of farnesyltransferase inhibitors: A comparative molecular field analysis approach, Bioorg. Med. Chem. Lett. 16 (2006), pp. 1821-1827.
17. D.S. Puntambekar, R. Giridhar, and M.R. Yadav, Understanding the antitumor activity of novel tricyclic piperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA, ur. J. Med. Chem. 41 (2006), pp. 1279-1292.
18. A. Lu, J. Zhang, X. Yin, X. Luo, and H. Jiang, Farnesyltransferase pharmacophore model derived from diverse classes of inhibitors, Bioorg. Med. Chem. Lett. 17 (2007), pp. 243-249.
19. T. Equbal, O. Silakari, G. Rambabu, and M. Ravikumar, Pharmacophore mapping of diverse classes of farnesyltransferase inhibitors, Bioorg. Med. Chem. Lett. 17 (2007), pp. 1594-1600.
20. A. Xie, P. Sivaprakasam, and R.J. Doerksen, 3D-QSAR analysis of antimalarial farnesyltransferase inhibitors based on a 2,5-diaminobenzophenone scaffold, Bioorg. Med. Chem. 14 (2006), pp. 7311-7323.
21. M.K. Gupta and Y.S. Prabhakar, QSAR study on tetrahydroquinoline analogues as plasmodium protein farnesyltransferase inhibitors: A comparison of rationales of malarial and mammalian enzyme inhibitory activities for selectivity, Eur. J. Med. Chem. 43 (2008), pp. 2751-276.
22. G.A. McConkey, Targeting the shikimate pathway in the malaria parasite Plasmodium falciparum, Antimicrob. Agents Chemother. 43 (1999), pp. 175-177.
23. M. Calas, M.L. Ancelin, G. Cordina, P. Portefaix, G. Piquet, V. Vidal-Sailhan, and H. Vial, Antimalarial activity of compounds interfering with Plasmodium falciparum phospholipids metabolism: Comparison between mono- and bis-quaternary ammonium salts, J. Med. Chem. 43 (2000), pp. 505-516.
24. R. McLeod, S.P. Muench, J.B. Rafferty, D.E. Kyle, E.J. Mui, M.J. Kirisits, D.G. Mack, C.W. Roberts, B.U. Samuel, R.E. Lyons, M. Dorris, W.K. Milhous, and D.W. Rice, Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I, Int. J. Parasitol. 31 (2001), pp. 109-113.
25. T. Joet, U. Eckstein-Ludwig, C. Morin, and S. Krishna, Validation of the hexose transporter of Plasmodium falciparum as a novel drug target, Proc. Natl. Acad. Sci. USA 100 (2003), pp. 7476-7479.
26. M.H. Gelb, W.C. Van Voorhis, F.S. Buckner, K. Yokoyama, R. Eastman, E.P. Carpenter, C. Panethymitaki, K.A. Brown, and D.F. Smith, Protein farnesyl and N-myristoyl transferases: Piggy-back medicinal chemistry targets for the development of antitrypanosomatid and antimalarial therapeutics, Mol. Biochem. Parasitol. 126 (2003), pp. 155-163.
27. E. Nduati, S. Hunt, E.M. Kamau, and A. Nzila, 2,4-Diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: A novel class of antimalarials, Antimicrob. Agents Chemother. 49 (2005), pp. 3652-3657.
28. R.D. Brown and Y.C. Martin, Use of structure-activity data to compare structure-based clustering methods and descriptors for use in compound selection, J. Chem. Inf. Comp. Sci. 36 (1996), pp. 572-584.
29. SYBYL, Version 7.3, 2006, Tripos associates, St. Louis (MO), USA.
30. R.T. Eastman, J. White, O. Hucke, K. Bauer, K. Yokoyama, L. Nallan, D. Chakrabarti, C.L. Verlinde, M.H. Gelb, P.K. Rathod, and W.C. Van Voorhis, Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum, J. Biol. Chem. 280 (2005), pp. 13554-13559.
31. M. Clark, R.D. Cramer III, and N.V. Opdenbosch, Validation of the general-purpose tripos 5.2 force field, J. Comput. Chem. 10 (1989), pp. 982-1012.
32. R.D. Cramer III, D.E. Patterson, and J.D. Bunce, Comparative molecular field analysis (CoMFA): 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110 (1988), pp. 5959-5967.
33. G. Klebe, U. Abraham, and T. Mietzner, Molecular similarity indices in a comparative analysis (COMSIA) of drug molecules to correlate and predict their biological activity, J. Med. Chem. 37 (1994), pp. 4130-4146.
34. V.N. Viswanadhan, A.K. Ghose, G.R. Revenkar, and R.K. Robins, Atomic physicochemical parameters for three-dimensional structure-directed quantitative structure-activity relationships: 4. Additional parameters for hydrophobic and dispersive interactions and their application for an automated superposition of certain naturally occurring antibiotics, J. Chem. Inf. Comp. Sci. 29 (1989), pp. 163-172.
35. G. Klebe, The use of composite crystal-field environments in molecular recognition and the de novo design of protein ligands, J. Mol. Biol. 237 (1994), pp. 212-235.
36. L. Stahle and S. Wold, Multivariate data analysis and experimental design in biomedical research, Progr. Med. Chem. 25 (1988), pp. 291-338.
37. R.D. Cramer III, J.D. Bunce, and D.E. Patterson, Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies, Quant. Struct. -Act. Relat. 7 (1988), pp. 18-25.
38. D.M. Hawkins, S.C. Basak, and D. Mills, Assessing model fit by cross-validation, J. Chem. Inf. Comp. Sci. 43 (2003), pp. 579-586.